Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Ferro

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Drugs|January 1, 1996
The clinical potential of endothelin receptor antagonists in cardiovascular medicineC J Ferro, D J Webb
Drugs|January 1, 1997
Endothelial dysfunction and hypertensionC J Ferro, D J Webb
International Journal of Clinical Practice|September 22, 2012
Randomised-controlled trials in chronic kidney disease--a call to arms!K P Ng, J N Townend, C J Ferro
QJM : Monthly Journal of the Association of Physicians|April 12, 2012
Hypertension, arterial haemodynamics and left ventricular disease: historical observationsC J Ferro, R P Steeds, J N Townend
The New England Journal of Medicine|August 8, 1998
Bosentan in essential hypertensionW G Haynes, C J Ferro, D J Webb
Journal of Cardiovascular Pharmacology|May 22, 1998
Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's diseaseP J Smith, C J Ferro, D S McQueen, et al.
Circulation|June 25, 1998
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivoC J Ferro, J C Spratt, W G Haynes, et al.
Rheumatology (Oxford, England)|May 5, 2007
Myocardial disease in systemic vasculitis and autoimmune disease detected by cardiovascular magnetic resonanceN C Edwards, C J Ferro, J N Townend, et al.
British Journal of Clinical Pharmacology|May 21, 1999
Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's diseaseP J Smith, C J Ferro, D S McQueen, et al.
Heart (British Cardiac Society)|March 27, 2009
Is lowering phosphate exposure the key to preventing arterial stiffening with age?C J Ferro, C D Chue, R P Steeds, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Drugs|January 1, 1996
The clinical potential of endothelin receptor antagonists in cardiovascular medicineC J Ferro, D J Webb
Drugs|January 1, 1997
Endothelial dysfunction and hypertensionC J Ferro, D J Webb
International Journal of Clinical Practice|September 22, 2012
Randomised-controlled trials in chronic kidney disease--a call to arms!K P Ng, J N Townend, C J Ferro
QJM : Monthly Journal of the Association of Physicians|April 12, 2012
Hypertension, arterial haemodynamics and left ventricular disease: historical observationsC J Ferro, R P Steeds, J N Townend
The New England Journal of Medicine|August 8, 1998
Bosentan in essential hypertensionW G Haynes, C J Ferro, D J Webb
Journal of Cardiovascular Pharmacology|May 22, 1998
Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's diseaseP J Smith, C J Ferro, D S McQueen, et al.
Circulation|June 25, 1998
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivoC J Ferro, J C Spratt, W G Haynes, et al.
Rheumatology (Oxford, England)|May 5, 2007
Myocardial disease in systemic vasculitis and autoimmune disease detected by cardiovascular magnetic resonanceN C Edwards, C J Ferro, J N Townend, et al.
British Journal of Clinical Pharmacology|May 21, 1999
Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's diseaseP J Smith, C J Ferro, D S McQueen, et al.
Heart (British Cardiac Society)|March 27, 2009
Is lowering phosphate exposure the key to preventing arterial stiffening with age?C J Ferro, C D Chue, R P Steeds, et al.
Pageof 4